由于成本和效益有限,国民保健制度可能无法涵盖高成本的阿尔茨海默氏性痴呆症药物。 NHS may not cover high-cost Alzheimer's drug donanemab due to cost and limited benefits.

联合王国国家保健服务(NHS)可能无法覆盖Eli Lilly的老年痴呆症药物Donanemab, 原因是其成本高昂, The UK's National Health Service (NHS) may not cover Eli Lilly's Alzheimer's drug, donanemab, due to its high cost, despite its potential to significantly slow cognitive decline. 在对另一种药物 lecanemab 做出类似决定后，专家们担心 donanemab 可能面临同样的命运，该药物被认为对其有限的益处来说过于昂贵。 Following a similar decision on another drug, lecanemab, which was deemed too costly for its limited benefits, experts worry donanemab could face the same fate. 这两种药物都是针对氨基胺积聚的,但据报告产生了严重的副作用。 Both drugs target amyloid buildup, but serious side effects have been reported. 预计不久将作出关于Donanemab的决定。 A decision on donanemab is expected soon.